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IMMUNOEXTRACTION AND REVERSE DISPLACEMENT
IMMUNOASSAY: ANALYSIS OF FREE DRUG FRACTIONS
John E. Schiel, Zenghan Tong, Chainarong Sakulthaew, and David S. Hage*
Department of Chemistry, University of Nebraska-Lincoln, Lincoln, Nebraska 68588-0304
Abstract
A flow-based method employing a reverse displacement immunoassay was combined with
ultrafast immunoextraction and near-infrared fluorescence detection for the analysis of free drug
fractions, using phenytoin as a model analyte. Factors considered in the design of this method
included the sample application conditions, the design of the immobilized drug analog column, the
utilization of antibodies or Fab fragments as labeled binding agents, and the label application and
column regeneration conditions. In the final method, sample injections led to the displacement of
labeled binding agents from an immobilized phenytoin analog column. This displacement peak
appeared within 20–30 s of sample injection and was proportional in size to the free phenytoin
concentration in the sample. It was possible with this method to regenerate the column by using
only the application of additional label between sample injections. This method was used to
measure clinically-relevant concentrations of free phenytoin in serum and drug/protein mixtures
and gave good correlation with ultrafiltration, while also being faster to perform and requiring
significantly less sample. This technique was not limited to free phenytoin measurements but
could be adapted for other drugs or analytes through the use of appropriate columns and binding
agents.
INTRODUCTION
Many drugs bind reversibly with serum proteins, creating both a protein-bound fraction and
a free fraction in the circulation. The free fraction is often thought to represent the active
form of a drug because it is capable of crossing membranes and interacting with
receptors.1–3 Although a drug’s total concentration is often used in pharmaceutical testing,
the relationship between the total concentration and free fraction of a drug can be affected
by factors such as illness, trauma, surgery, or age.3 Problems that arise because of these
effects have created an ongoing need for rapid and accurate methods that can directly
measure free drug fractions.1,4
Phenytoin is a common antiepileptic drug that is highly bound (e.g., 90%) in blood to human
serum albumin (HSA)3–7 (see Refs. [3] and [5] for more details on the binding sites that are
involved in this interaction and drugs or other solutes that may affect this binding).
Equilibrium dialysis and ultrafiltration are often used to isolate free phenytoin fractions from
clinical samples, but these methods tend to have long analysis times, problems with non-
specific binding, and require a separate technique (e.g., HPLC) to measure the free drug
fraction.1,4,6,7 Restricted access media (RAM) columns have also been used to isolate free
phenytoin fractions from drug/protein mixtures but have not been used for this purpose with
real clinical samples.8
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Another technique that has recently been developed for free drug measurements is an
ultrafast immunoextraction/displacement assay (UFIDA).4,9 This flow-based approach uses
an affinity microcolumn that contains immobilized antibodies for the drug of interest. These
antibodies are loaded with a labeled drug analog, which is displaced by the free fraction of a
drug during sample injection. This technique has been used with both near-infrared (NIR)
fluorescent labels and chemiluminescent labels and provides good agreement with reference
methods.4,9 One possible limitation of this approach is that the retained analyte does have to
be eluted and the column regenerated on a regular basis. This requirement limits the sample
throughput of this approach and can add a significant amount of time to the overall
analysis.4,9,10
This report will explore a new flow-based approach for free drug measurements based on
ultrafast affinity extraction and a reverse displacement immunoassay (RDIA). Phenytoin
will be used as the model analyte in this work. The general scheme for this approach is
given in Figure 1. First, a labeled binding agent (or “label”) will be applied to an affinity
microcolumn containing an immobilized analog of the target drug, or a structurally-related
species.10–12 After excess label has been washed away, a sample containing the analyte and
proteins will be injected. This sample will be passed through the microcolumn on a
sufficiently small timescale to minimize dissociation for the drug from binding proteins in
the sample.4,9 Under these conditions, only the drug’s free fraction should displace the label
from the column, giving a displacement peak that is proportional to the sample
concentration of the free drug.
The RDIA method is similar to a one-site immunometric method, in which an immobilized
analog of the analyte is also used to bind to the label.10–13 However, the one-site
immunometric assay uses a relative large amount of the immobilized analog to extract
excess label from a pre-incubated mixture of this label with the sample, with the remaining
analyte-label complex in solution then being detected.10,13 In contrast to this, a signal is
produced in an RDIA through the displacement of label by the analyte from a small
immobilized analog column. This approaches means that no pre-incubation of the sample
and label is required in the RDIA method, thus leading to shorter analysis times than a one-
site immunometric assay. Another potential advantage of an RDIA over both a one-site
immunometric method and the UFIDA is that no elution/regeneration step, other than the
application of more label, should be needed between sample injections. The expected result
is a relatively rapid method that can be employed for the direct analysis of free drug
fractions or other analytes in complex samples.
EXPERIMENTAL
Reagents
The phenytoin (99% pure), HSA (>96%, essentially fatty acid free) and commercial sample
of pooled human serum (negative for hepatitis B or C and HIV; handled with standard
precautions for bloodborne pathogens) were from Sigma-Aldrich (St. Louis, MO). Reagents
for the bicinchoninic acid (BCA) assay were from Pierce (Rockford, IL). The 3-N-
amino-5,5-diphenylhydantoin (ADPH) was from Ryan Scientific (Mount Pleasant, SC). The
glutaraldehyde was obtained from Fisher Scientific (Fairlawn, NJ). The IRDye 800 CW N-
hydroxysuccinimide (NHS) ester was from Li-Cor (Lincoln, NE). The monoclonal anti-
phenytoin antibodies (clone 16302, protein A purified from ascites fluid) were purchased
from QED Biosciences (San Diego, CA). The Nucleosil Si-1000 (1000 Å pore size, 5 µm
particle size) and Nucleosil Si-300 (300 Å pore size, 7 µm particle size) were from
Macherey Nagel (Düren, Germany). All aqueous solutions were prepared using water from a
Nanopure system (Barnstead, Dubuque, IA). All other chemicals were reagent grade or
better.
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Apparatus
The Vivaspin 6 PES membrane concentrators (30 kDa MW cutoff) and 5702RH temperature
controlled centrifuge were from VWR (West Chester, PA). The Zeba Desalt spin columns
were from Pierce. Ultrafiltration was performed using Centrifree Micropartition devices (30
kDa MW cutoff, 0.15–1.5 mL sample capacity) from Amicon (Danvers, MA). Columns
were packed using an Alltech 1666 slurry packer (Deerfield, IL).
The HPLC system contained two PU-2080 pumps, a CO-2057 column oven, and an
AS-2057 autosampler from Jasco (Easton, MD). The autosampler was equipped with a 100
µL loop and operated in the partial loop injection mode. This system was controlled using a
Jasco LC-Net II system controller and EZ Chrom SI software (Scientific Software,
Pleasanton, CA). A Jasco UV-2075 absorbance detector was used with this system to
examine the ultrafiltration samples, which were injected onto a 5 cm × 4.6 mm i.d. column
containing HSA immobilized to Nucleosil Si-300.14,15 For the RDIA method, the HPLC
system included a custom-built NIR fluorescence detector supplied by Li-Cor, as described
previously.9,16 All peaks were integrated using PeakFit 4.12 (Systat Software, San Jose,
CA); moments analysis was performed by using the residual option of this program and an
EMG-GMG fit with a linear progressive baseline.
Preparation of affinity microcolumns
A support using immobilized ADPH as an analog of phenytoin was prepared using
Nucleosil Si-1000 silica (see Supplemental Material for details). The silica was first
converted into a diol form and oxidized with periodate to generate aldehyde groups,14,15
giving the starting material shown in Figure 2. This aldehyde-activated support was reacted
with oxalic dihydrazide at pH 5.0.14 The dihydrazide silica was then combined at pH 5.0
with an excess of glutaraldehyde, followed by the addition of ADPH and sodium
cyanoborohydride at pH 6.0. This support was later treated with sodium borohydride at pH
8.0 to remove any remaining aldehyde groups.14,15 The ADPH content of the final support
was estimated with a BCA assay16 to be a maximum of 1–2 µmol ADPH/g silica. A control
support was prepared in the same manner but with no ADPH being added during the
immobilization step. The ADPH support and control support were packed into separate 1
mm × 2.1 mm I.D. columns at 3000 psi (20.7 MPa) using pH 7.4, 0.067 M phosphate buffer
as the packing solution. All columns were stored at 4°C in pH 7.4, 0.067 M potassium
phosphate buffer when not in use.
Preparation of labeled antibodies and Fab fragments
The anti-phenytoin monoclonal antibodies were placed into pH 8.5, 0.10 M potassium
phosphate buffer by using a Vivaspin concentrator and adjusted to a concentration of ~1 mg/
mL. A 0.1–0.22 mg portion of IRDye 800 CW NHS ester was dissolved in 25 µL water and
a 7.5 µL aliquot was combined with 1 mL of the pH 8.5 antibody solution. This mixture was
shaken for 2 h in the dark at room temperature. A Zeba desalt spin column eluted with pH
7.4, 0.067 M potassium phosphate buffer was used to separate the labeled antibodies from
the unreacted dye. Absorbance measurements at 780 and 280 nm were used to determine the
dye/protein ratio and the approximate antibody concentration of this mixture. The labeled
antibodies had a final concentration of 0.4–0.8 mg/mL and a dye/protein ratio of 0.5–1.5.
These labeled antibodies were stored at 4°C in pH 7.4, 0.067 M phosphate buffer prior to
further experiments.
Fab fragments were generated from the anti-phenytoin monoclonal antibodies by using a
mouse IgG1 Fab and F(ab’)2 preparation kit from Pierce (Rockford, IL). The Fab fragments
were separated from the Fc fragments and undigested antibodies by collecting the non-
retained fraction of the digest that passed through a protein A column, as supplied with the
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kit. The Fab fragments were stored in pH 8.5, 0.1 M potassium phosphate buffer at −80°C
prior to labeling. The labeling of the Fab fragments with IRDye 800 CW NHS ester, and the
purification and characterization of the labeled Fab fragments, was carried out in the same
manner as described for the labeled antibodies. This preparation had a dye/protein ratio of
4.2 and a final Fab concentration of 0.13 mg/mL. The labeled Fab fragments were stored at
4°C in pH 7.4, 0.067 M phosphate buffer.
RDIA and ultrafiltration
All experiments were performed in duplicate or triplicate at 37°C. In the RDIA method, pH
7.4, 0.067 M potassium phosphate buffer was used for sample or label injection and pH 2.5,
0.067 M phosphate buffer was utilized for column regeneration. The final RDIA method
used an injection of 100 pmol label at 0.1 mL/min, followed by a switch to 1.2 mL/min for
the injection of a 20 µL sample. After the displacement peak had appeared, a switch was
made to 0.1 mL/min and more label was applied prior to the next sample injection. For
column regeneration, the flow rate was switched to 1 mL/min for the application of pH 2.5
elution buffer, followed by application of the pH 7.4 buffer at 1 mL/min and label at 0.1 mL/
min.
In the ultrafiltration experiments, a 1 mL aliquot of each sample was added to a Centrifree
micropartition device, which was then centrifuged at 37°C for 45 min at 1500 × g. To
measure the free phenytoin concentration, the filtrate of each sample was collected and 20
µL was injected in duplicate at 0.5 mL/min onto a 5 cm × 4.6 mm i.d. HSA column in pH
7.4, 0.067 M potassium phosphate buffer and with detection at 205 nm, as described
previously.9
RESULTS AND DISCUSSION
General method design and initial column development
The key components for the scheme shown in Figure 1 for the RDIA method can be
represented by the following reactions.
(1)
(2)
Eq (1) represents the binding and dissociation of the immobilized analyte analog (I) with the
labeled binding agent or “label” (L) in the affinity column, where this process creates a local
pseudo-equilibrium between the free and bound states for L. The terms ka,LI and kd,LI
represent the second-order association and first-order dissociation rate constants for this
process. Eq (2) represents the binding that can then occur between an injected analyte (A)
and the label that is present in a non-bound state in the mobile phase, where ka,LI is the
second-order association rate constant for this reaction.
For the system in eqs (1–2), the labeled binding agent has already been applied to the
column, allowed to bind to the immobilized analog, and excess label has been washed from
the column. However, even after excess label has been removed, a small amount of the
retained label will dissociate from the immobilized analog and either rebind to the column or
interact with an injected analyte. The formation of a complex between the label and the
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analyte (L-A) is what leads to the formation of a displacement peak and the measured signal
for this assay. If a small column and reasonably fast flow rate are used for this method, as
employed in this report, the dissociation of L-A back to the analyte and non-bound label
within the column can be assumed to be negligible on the time scale of the experiment.
Two factors that were originally considered for the development of an RDIA method for
free drug measurements were the column size and flow rate that were employed. It is known
that the accurate measurement of free drug fractions by ultrafast affinity extraction requires
that a sample be passed through the extraction column quickly enough to minimize
dissociation of the protein-bound form of the drug in the sample.4,9,18 In a previous UFIDA
method for measuring free phenytoin, an extraction time of 140 ms was found to be suitable
for such work.9 The same extraction time was created in this current study by injected
samples at a flow rate of 1.2 mL/min onto a 1 mm × 2.1 mm I.D. affinity microcolumn. The
support that was placed within this column is shown in Figure 2 and contained an
immobilized analog of phenytoin. The ability of this support to bind labeled anti-phenytoin
antibodies was tested by injecting 100 pmol of this label at 0.1 mL/min, followed by an
injection at 1.2 mL/min of a 100 µL sample of 50 µM phenytoin (i.e., a concentration ten-
times that seen for free phenytoin in serum at therapeutic levels).9,19 As illustrated in Figure
3, a large displacement peak was observed under these conditions. However, little or no
displacement peak was seen when a control column was used in place of the drug analog
column or when only buffer was injected after the label onto the drug analog column (see
Supplemental Material for examples).
In the RDIA method it was not necessary to restrict the extraction time for the label to the
millisecond time domain. This meant that a lower application flow rate could be used for the
label than for the sample, as has also been noted for the UFIDA method.9 The use of a
slower flow rate for label application (i.e., 0.1 vs. 1.2 mL/min) was found to increase the
signal of the displacement peaks by six- to seven-fold. This increase was believed to be due
to the more efficient capture of the label as it was allowed more time for binding to the
immobilized drug analog. A similar effect has been observed in other flow-based
immunoassays and is typically related to the adsorption-limited kinetics that are often
present for antibody-antigen interactions in the types of supports that were used in this
study.4,9,10
Another factor found to affect the ability of the label to bind to the extraction column was
the length of the spacer arm between the drug analog and the support. The reaction scheme
in Figure 2 provided a seventeen-atom spacer between the drug analog and the support,
which was the material used throughout the remainder of this report. Another support that
was originally considered had the drug analog attached to aldehyde-activated silica through
the Schiff base method, creating a six-atom spacer (see Supplemental Material for further
details). This material was slightly easier and faster to make than the one in Figure 2, used
the same site of attachment for the drug analog, and contained an equal or greater amount of
the immobilized drug analog. Neither of these two materials or spacer arms gave any
significant amount of non-specific binding to the label or measurable displacement peaks
when used without the immobilized drug analog in the RDIA method. However, the support
with the shorter spacer arm did result in a seven- to eight-fold smaller signal in the RDIA
method than when the support with the larger spacer arm was utilized. The difference in
these signals was determined to be mainly related to steric restrictions that affected the
extent to which the labeled binding agent (e.g., antibodies) could interact with the
immobilized drug analog as the spacer arm was decreased in length.
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Method optimization
Several other factors were considered during the development of the RDIA method. As
suggested by the scheme in eqs (1–2), one of these factors was the amount of label that was
employed. To optimize this parameter, the quantity of applied label was varied while the
resulting displacement peak was measured for a 100 µL sample of 50 µM phenytoin. As the
amount of applied label was decreased below 100 pmol, a linear decrease in the size of the
displacement peak was produced. However, the displacement peak began to show a
nonlinear response as more than 100 pmol label was applied. Thus, a 100 pmol portion of
labeled antibodies, or labeled Fab fragments, was used in all further experiments. A load of
100 pmol label represented at least a 30- to 60-fold excess versus the total estimated amount
of immobilized drug analog in the affinity microcolumn; the actual excess was even higher
because the label was able to bind to less than a third of the immobilized analog, as
determined later in this section. This fact meant that only a small fraction of the label was
binding to this column even at 0.1 mL/min, as confirmed experimentally. It should be
possible in future work with the RDIA method to recapture and recycle this non-retained
label for use in later cycles, thus helping to further reduce the amount of label that is needed
for this approach.
The initial testing of the RDIA method used a pH 2.5 elution step to regenerate the drug
analog column after label had been applied and a displacement peak for the sample had been
detected (i.e., a process taking 10–15 min per cycle). Additional experiments examined
whether multiple samples could be injected after one application of the label to the drug
analog column. This was tested by applying 100 pmol of label followed by a series of 20 µL
injections of 5 µM phenytoin (i.e., a typical concentration for free phenytoin in serum).
When compared to the displacement peak for the first sample injection, the second, third and
fourth injections gave displacement peaks that were 32%, 59%, and 63% smaller. The
displacement peaks for further injections decreased even more in size. This was not
surprising because the accumulated stoichiometric amount of injected phenytoin after four
injections (i.e., 0.4 pmol) approached the estimated amount of retained label in the column
(i.e., a maximum of 1.5–3 pmol). Although these results indicated that not all the label was
displaced after a single sample injection, the amount of label that was displaced by one
sample did affect the signal that was obtained for later samples if no additional label had
been applied between injections. From this experiment it was estimated that 13–27% of the
immobilized analog groups on the support were immunologically active and available for
binding to the label under the given application conditions.
Further experiments were carried out in which a fixed amount of label was applied between
samples while pH 7.4 buffer was continuously passed through the system. In this case, 100
pmol of label was applied between 100 µL injections of 50 µM phenytoin (i.e., 5 pmol
analyte, or at least a 1.6- to 3.2-fold excess versus label that was adsorbed to the column). In
this case, the displacement peak for the second sample showed an increase of 22.5% in its
displacement peak when compared to the first sample injection. The next three injections
showed only a variation of 4.7% in their displacement peaks, and the fourth and fifth
injections gave peaks that varied by only 0.4%. These results indicated that the simple
reapplication of label between sample injections could be used to regenerate the column.
This approach added only a few minutes to the analysis and was much faster than the 10–15
min required for column regeneration when using both a pH 2.5 elution step and label
application. Thus, the application of only label between sample injections was used in all
further experiments unless otherwise indicated.
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Response of RDIA method
Some typical calibration curves for the RDIA method are shown in Figure 4. When these
results were plotted as a function of analyte concentration, a non-linear change in response
was observed. An essentially identical response and calibration range was obtained when
using equal amounts of labeled antibodies or labeled Fab fragments. This information
indicated that the curvature of these plots was not the result of using bivalent instead of
monovalent binding agents as the labeled species (e.g., intact antibodies versus Fab
fragments). An alternative explanation suggested by the model in eqs (1–2) and the results in
the previous sections was that this curvature was at least partly a result of the kinetic
processes occurring in the RDIA method.10,18 Thus, a second set of calibration curves were
prepared in which the response of the assay was plotted as a function of the logarithm of the
analyte concentration. The plots obtained for the assay response versus log(analyte
concentration) appeared to follow a linear response over the range of phenytoin
concentrations that were tested (correlation coefficient = 0.986–0.987, n = 6–7). This linear
response was observed when using either labeled antibodies or labeled Fab fragments in the
assay. Such a response suggested that the assay signal could be described, to an initial
approximation, by using eq (2) and a pseudo-first order reaction between the injected
analyte and labeled binding agent in the mobile phase. Further studies are being planned to
examine the theoretical basis of this response in more detail.
As noted for other flow-based assays involving similar supports, the response of this method
was found to be related to the moles of injected analyte.10,18 One practical consequence of
this relationship was that a change in sample volume could be used to adjust the position and
response of a concentration-based calibration curve for this assay. For instance, an increase
in sample volume from 10 µL to 20 µL would double the moles of analyte that were applied
with each injection, thus shifting a concentration-based calibration curve for the assay to a
two-fold lower range in concentration (Note: a calibration curve based on the moles of
injected analyte would not be affected by the same change in sample volume). In this report,
a sample volume of 20 µL was used in the final method to match the usable calibration
range with the concentrations of free phenytoin that would be expected in serum at
therapeutic levels.
Another item that was considered was the effect of HSA on the RDIA method. This was of
interest because HSA has a high concentration in serum and is known to bind to phenytoin
and structurally-related compounds.3–7,20 It was found that a sample containing 550 µM
HSA (i.e., a representative serum concentration)19,21 did give a reproducible displacement
peak in the RDIA method; however, this peak was smaller (i.e., 25–30% or less) than the
displacement peaks seen for free phenytoin in spiked serum or representative phenytoin/
HSA mixtures. The NIR fluorescent dye used in this report as a label is known to have little
or no change in its fluorescence in the presence of serum or HSA9 and has no appreciable
binding to HSA. Thus, the peak observed during the injections of HSA in the RDIA method
was probably due to the displacement of label as this protein bound to the drug analog
column. In this study, a correction for this effect was made for all drug/HSA mixtures and
serum samples by subtracting the results for an HSA standard or serum sample that did not
contain any phenytoin. This approach was satisfactory for this current report, but alternative
approaches for avoiding or minimizing this effect are currently being examined.
Performance of RDIA method
Under the conditions employed in Figure 4, the lower limit of detection for the RDIA
method was estimated to be 27–29 pmol (i.e., 1.3–1.4 µM for a 20 µL sample) at a signal-to-
noise ratio of three when using either labeled antibodies or labeled Fab fragments. The upper
limit of detection extended to at least 160–200 pmol (i.e., 8–10 µM for a 20 µL sample).
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This dynamic range was a good match with the levels expected for free phenytoin in clinical
samples.9,19 The fact that the lower and upper limits of detection were larger than the
amount of retained label in the drug analog column indicated that only a fraction of the
analyte was required to displace this label for detection. This feature was attractive for the
measurement of free drug fractions, where minimal perturbation of the sample is desired. In
addition, this feature suggested that longer drug analog columns and slower flow rates could
be used in other applications of the RDIA method to provide lower limits of detection by
allowing for more efficient displacement of the label by the analyte.
As shown in Figure 3, displacement peaks were obtained within 20–30 s of sample injection.
The total time per analysis, when using the injection of label between samples and no pH
step for elution, was less than 5–10 min per sample once two more applications of label had
been made onto the drug analog column. The method was also found to be robust. For
instance, the two sets of curves in Figure 4 were obtained using different batches of the drug
analog support and labeled agent, yet these curves still gave a consistent response and
calibration range. In addition, the amount of drug analog support that was required per
column was only a few milligrams and each drug analog column could be used for several
months and hundreds of cycles with no significant signs of degradation.
The accuracy of this method was tested by using it to measure the free concentration of
phenytoin in both mixtures of this drug with physiological concentrations of HSA and in
serum spiked with phenytoin, with the latter being used as a representative clinical sample
(Note: additional clinical samples will be considered in future studies). The results are
summarized in Table 1. Identical samples were examined by using ultrafiltration as a
reference method to measure the free drug fractions.9 The RDIA results differed from those
obtained by ultrafiltration by only 4–11% and all overlapped within ±1 standard error of the
mean for the reference values. As has been observed for the UFIDA method, the overall
assay precision in the RDIA technique was mainly determined by factors that affected the
amount of label that was present for each injection (e.g., the amount of injected label, the
timing of the label and assay injections, and the flow rate).4,9,10 The precision of the RDIA
method for the tested samples was 7–23% (average coefficient of variation, 13%), which
was comparable to or slightly higher than the 4–13% (average, 7%) seen when using
ultrafiltration. However, the RDIA method was significantly faster than the ultrafiltration
method, which had a total analysis time of at least 1 hour per sample.9 The RDIA method
also required much smaller amounts of sample than ultrafiltration (i.e., 20 µL versus 1.0
mL).
CONCLUSIONS
This report described the development of an RDIA method as a new format for flow-based
immunoassays. This approach was illustrated by using the detection of free drug fractions of
phenytoin as a model. Several factors were considered in the creation and optimization of
this assay, such as the sample application conditions, the design of the affinity support, the
amount and type of label that was applied, and approaches for regenerating the column
between sample injections. The final assay was found to be a robust method that produced a
signal within 20–30 s of sample injection. This technique gave good correlation with
ultrafiltration for samples containing clinically-relevant levels of free phenytoin; however,
the RDIA method required much less time and sample to perform these measurements.
The RDIA method is not limited to phenytoin or the measurement of free drug fractions but
could be applied to any analyte for which an appropriate label and immobilized analyte
analog (or structurally related agent)10–12 is available or can be developed. The use of an
immobilized analog of the analyte should provide a stable support that can be utilized with a
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variety of elution conditions, as has been noted for other methods that use similar materials
(e.g., a one-site immunometric assay).10–13 The fact that the label, rather than a sample
component, is bound to the immobilized analog and used for signal generation is another
attractive feature. As an example, it was shown in this report that this feature makes it
possible to regenerate a phenytoin analog column by simply applying more label between
sample injections. The fact that the RDIA method eliminates the need for any pre-incubation
of the sample with a labeled binding agent or the need for a separate elution buffer should
lead to a significant reduction in analysis time for this approach when compared to other
flow-based immunoassays (e.g., the UFIDA method, one-site immunometric assay, and
traditional displacement assays).4,9,10–13 These advantages make the RDIA method
attractive for future work requiring the high-throughput analysis of drugs or biological
agents in pharmaceutical and clinical samples.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
General scheme for a reverse displacement immunoassay (RDIA). Symbols: ( ),
immobilized drug analog; ( ), labeled monoclonal antibody or Fab fragments (i.e., the
"label"); (○), drug or target analyte; ( ), serum protein or binding agent in the sample.
Schiel et al. Page 11
Anal Chem. Author manuscript; available in PMC 2012 December 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Preparation of a silica support containing an immobilized analog of phenytoin.
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Figure 3.
Typical displacement peaks obtained by the RDIA method for 100 µL sample injections of
50, 10, 5, 1, or 0.1 µM phenytoin (top-to-bottom). These displacement peaks were obtained
at 1.2 mL/min and pH 7.4 with only re-application of label between samples being used for
column regeneration.
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Figure 4.
Calibration curves obtained by the RDIA method for phenytoin when using (a) labeled anti-
phenytoin antibodies or (b) labeled anti-phenytoin Fab fragments. These results were
obtained for 20 µL sample injections. Other conditions were the same as in Figure 3 or as
given in the text. All of these measurements were made in duplicate or triplicate; the typical
precisions that were obtained are summarized in the text. The use of six calibration
standards in (a) instead of the seven used in (b) simply reflects that different amounts of
each type of label that were available at the different times at which these studies were
conducted; however, the overall range and response of the two curves are otherwise quite
similar.
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Table 1
Determination of free phenytoin concentrations by ultrafiltration and RDIA
Measured Free Phenytoin Conc. (µM)a
Sample Ultrafiltration RDIA
550 µM HSA + 10 µM Phenytoin 2.4 (±0.3) 2.6 (±0.6)
550 µM HSA + 16 µM Phenytoin 3.7 (±0.2) 4.1 (±0.3)
Serum + 12 µM Phenytoin 2.5 (±0.1) 2.4 (±0.2)
a
All measurements were made in duplicate or triplicate at 37°C and in pH 7.4, 0.067 M potassium phosphate buffer. The values in parentheses
represent ±1 standard error of the mean. The data for the drug/protein mixtures were obtained using labeled antibodies and the serum results were
obtained using labeled Fab fragments.
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SUPPLEMENTAL MATERIAL  
Immobilization of ADPH to Silica by the Schiff Base Method.  The coupling of 3-N-
amino-5,5-diphenylhydantoin (ADPH) directly to aldehyde-activated silica through the Schiff 
base method was one immobilization approach that was initially considered in this report, as 
adapted from the literature for the immobilization of proteins or other amine-containing agents.
1,2
  
The basis of this method is illustrated in Figure 1s.  In this approach, two samples of 0.6 g 
Nucleosil Si-1000 diol silica were placed into separate containers.  One sample was used to make 
the immobilized ADPH silica and the other served as a control support taken through all 
immobilization steps except addition of ADPH.  A 20 mL portion of a 90% acetic acid solution 
and 1 g sodium periodate were added per g silica to each sample and allowed to shake for two 
hours at room temperature to convert the diol silica into an aldehyde form.  These samples were 
then washed six times with water and three times with pH 6.0, 0.1 M potassium phosphate 
buffer.  Approximately 10 mL of pH 6.0, 0.1 M potassium phosphate buffer per g silica was used 
to suspend the silica and combined with 16 mg ADPH per g silica (added to only one of the two 
samples) and 7.5 mg NaCNBH3 per g silica (added to both samples).  This slurry was allowed to 
gently rock at room temperature and in the dark for a period of 10 days. 
 After 10 days, the silica was washed three times with pH 8.0, 0.1 M potassium phosphate 
buffer, three times with a 50:50 mixture of ethanol and pH 8.0, 0.1 M potassium phosphate 
buffer, six times with ethanol, three times with a 50:50 mixture of ethanol and pH 8.0, 0.1 M 
potassium phosphate buffer, and four times with pH 8.0, 0.1 M potassium phosphate buffer.  The 
total volume was then brought to 15 mL per g silica by adding pH 8.0, 0.1 M potassium 
phosphate buffer.  A 25 mg portion of NaBH4 per g silica was then slowly added over the course 
of 90 min (note: do this addition with caution; the solution will bubble) with gentle suspension of 
the silica after each addition.  The contents were then washed three times with 0.5 M NaCl in pH 
2 
 
8.0, 0.1 M potassium phosphate buffer and three times with pH 7.4, 0.067 M potassium 
phosphate buffer.  The silica was brought to a final volume of 6 mL with pH 7.4, 67 mM 
potassium phosphate buffer, resulting in a slurry containing approximately 100 mg silica per mL.  
These slurries were stored at 4
o
C. 
The final method used for ADPH immobilization (see Figure 2 of the main manuscript) 
also began by converting diol silica to an aldehyde-activated form, as described for the Schiff 
base method.  This aldehyde-activated support was then reacted with oxalic dihydrazide at pH 
5.0, as described in the literature.
2,3
 The dihydrazide-activated silica was combined with 20 mL 
of pH 5.0, 0.1 M potassium phosphate buffer per gram silica.  A 0.6 mL portion of 25% (w/w) 
glutaraldehyde per g silica was added to the slurry (note: this value represented a five-fold mole 
excess of glutaraldehyde versus dihydrazide groups).  The mixture was shaken for three hours at 
room temperature.  The silica was washed three times with pH 6.0, 0.1 M potassium phosphate 
buffer and brought to a final volume of 10 mL per g silica.  The remainder of the procedure 
followed the steps described for the Schiff base method, starting with the addition of ADPH to 
one of the support samples and NaCNBH3 to both support samples.  The final supports were 
stored in pH 7.4 buffer at 4
o
C. 
Comparison of Immobilization Methods for ADPH.  Preliminary studies with the 
RDIA method were used to compare the response that was obtained on various supports that 
contained immobilized ADPH.  One of these supports had been immobilized by the Schiff base 
method and used a six-atom spacer arm to attach ADPH to the support, while the second method 
used a multi-step process that introduced a seventeen-atom spacer arm.  The reaction schemes 
that were used to prepare these two types of supports are provided in Figure 1s and Figure 2, 
respectively.   An application flow rate of 0.1 mL/min was used during these experiments to give 
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the label maximum time to interact with the immobilized ADPH.  In these preliminary studies, a 
flow rate of 0.1 mL/min was also used to inject the phenytoin samples and allow them adequate 
time to displace the label from each column.  The quantity of label that was injected in each of 
these experiments was 100 pmol.  The sample had a volume of 100 L and contained either 
potassium phosphate buffer to serve as a blank or 50 M phenytoin (i.e., 5 pmol phenytoin) as a 
positive control.  The amount of injected label represented at least a 30- to 60-fold excess versus 
the estimated total amount of immobilized drug analog in the column.  As indicated in the main 
body of the text, the concentration of phenytoin that was employed in this study was ten-times 
that seen for free phenytoin in serum at therapeutic levels.
4,5
     
 Figure 2s shows some typical displacement peaks that were obtained in the RDIA method 
under these conditions.  Injections of phenytoin samples onto both types of  
ADPH supports gave a displacement peak, as shown in Figures 2s(a)-(b); however, the peak 
obtained when using a seventeen-atom spacer arm between ADPH and the support was much 
larger than the signal for the support that used a six-atom spacer arm.  It was for this reason that 
the support with the seventeen-atom spacer arm was used in all further experiments.  The fact 
that these studies were conducted using a relatively long contact time for the sample with the 
column, thus minimizing kinetic effects, suggested that this difference was due to steric 
hindrance between the labeled binding agent and the immobilized ADPH when using the shorter 
spacer arm.  This conclusion agrees with previous observations that have been made in affinity 
chromatography in the use of short versus long spacer arms for the attachment of small ligands 
for use in the isolation of enzymes, proteins or other large targets.
2
    
Similar experiments based on the RDIA method were conducted using a control column 
in which the support contained the seventeen-atom spacer arm but no immobilized ADPH.  A 
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typical result obtained at an injection flow rate of 0.1 ml/min is shown in Figure 2s(c).  It was 
found in this type of experiment that very little labeled binding agent was retained by this 
support, leading to no significant displacement peak upon the injection of phenytoin.  Using an 
even higher injection flow rate (e.g., 1.2 ml/min) further reduced this background signal.  This 
low background signal in the absence of any immobilized ADPH indicated that little or no non-
specific interactions were occurring between the labeled binding agent and the support or the 
seventeen-atom spacer arm.  Low non-specific binding of human serum albumin and other serum 
components has also been noted in prior work using similar silica supports that were prepared by 
the Schiff base method or activated with hydrazide groups.
1,3,4
  These results confirmed that the 
displacement of the labeled binding agent in the RDIA method was from the immobilized ADPH 
and was not due to the release of this label from other components of the support, such as the 
spacer arm.   
Another set of control experiments were conducted in which the labeled binding agent 
was injected onto the immobilized ADPH supports followed by the injection of only phosphate 
buffer.  Figure 2s(d) shows the result that was obtained when using the ADPH support with the 
seventeen-atom spacer arm.  It was found that the injection of buffer produced no measurable 
displacement peak even though the same bound of labeled binding agent had been adsorbed to 
the immobilized ADPH column as was used in Figure 2s(a) for the injection of a phenytoin 
sample.  It was determined from this result that, under the injection conditions used in this study, 
the labeled binding agent did not have significant displacement from the ADPH column in the 
presence of only buffer.  Instead, the presence of phenytoin in the sample was required to 
combine with this labeled binding agent and displace it from the ADPH column.    
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Figure Legends 
Figure 1s.  Immobilization of 3-N-amino-5,5-diphenylhydantoin (ADPH) onto silica by the 
Schiff base method.  This scheme uses aldehyde-activated silica as the starting 
material, which can be prepared as described in the text. 
Figure 2s. Effect of ADPH support preparation method on displacement peak area in the 
RDIA method.  These results show displacement peaks that were obtained for 100 
μL injections of 50 μM phenytoin on (a) an immobilized ADPH column 
containing a seventeen-atom spacer arm, (b) an immobilized ADPH column 
containing a six-atom spacer arm, and (c) a control column containing a 
seventeen-atom spacer arm but no immobilized ADPH.  The result in (d) was 
obtained for a 100 μL injection of pH 7.4, 67 mM potassium phosphate buffer on 
the immobilized ADPH column containing a seventeen-atom spacer arm.  The 
displacement flow rate was 0.1 mL/min, with a pH elution step being used 
between the displacement and re-application of the label to the column.   
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